<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806272</url>
  </required_header>
  <id_info>
    <org_study_id>L-12-01</org_study_id>
    <nct_id>NCT01806272</nct_id>
  </id_info>
  <brief_title>Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis</brief_title>
  <official_title>A Open,Randomized Phase II Trial Comparing Local Use of rhGM-CSF and Compound Vitamin B12 Solution to Compound Vitamin B12 Solution Alone Treating Chemoradiotherapy-induced Oral Mucositis in Patients With Primary Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei LUO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open,randomized phase II trial comparing effectiveness and safety of local use of
      rhGM-CSF and Compound Vitamin B12 to Compound Vitamin B12 solution alone treating oral
      mucositis in primary nasopharyngeal cancer. The main end point is the incidence of grade II
      and less oral mucositis at the end of treatment.The hypothesis of the study is that the local
      use of rhGM-CSF and Compound Vitamin B12 can decrease the incidence of grade III and more
      oral mucositis at the end of treatment compared to local use of Compound Vitamin B12 alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

        1. Grade II oral mucositis induced by chemoradiotherapy in patient with primary
           nasopharyngeal carcinoma.

        2. Receiving 68-72 Gray of radiation dose.

        3. Age between 18 and 65 years.

        4. KPS≥70.

        5. Patient who has given his/her written consent before any specific procedure of the
           protocol.

      Exclusion Criteria:

        1. Severe uncontrolled infection.

        2. Pregnant or breast-feeding females.

        3. Allergy to this medicine.

        4. Diarrhea.

      Outcome measures:

        1. Grade of oral mucositis:NCI Common Terminology Criteria for Adverse Events v3.0, NCI
           CTCAE v3.0

        2. Pain: WHO,Numerical Rating Scale(NRS)

        3. Tumor response to chemoradiotherapy:Response Evaluation Criteria in Solid
           Tumors,RECIST1.1
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of grade II and less oral mucositis at the end of treatment</measure>
    <time_frame>7 weeks</time_frame>
    <description>Using the criteria of NCI CTCAE v3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cumulative incidence and time of different grade,using the criteria of WHO,NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence and time of grade III and more oral mucositis</measure>
    <time_frame>7 weeks</time_frame>
    <description>Using the criteria of NCI CTCAE v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysphagia</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cumulative incidence and time of different grade,using NCI CTCAE v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response to chemoradiotherapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Using the criteria of Response Evaluation Criteria in Solid Tumors1.1(RECIST1.1)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Nasopharyngeal Cancers</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
Radiotherapy: Intensity modulated radiation therapy(IMRT)
Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
Radiotherapy: Intensity modulated radiation therapy(IMRT)
Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGM-CSF</intervention_name>
    <description>The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>特尔立</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound Vitamin B12</intervention_name>
    <description>Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>贯新克</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Grade II oral mucositis induced by chemoradiotherapy in patient with primary
             nasopharyngeal carcinoma.

          2. Receiving 68-72 Gray of radiation dose.

          3. Age between 18 and 65 years.

          4. KPS≥70.

          5. Patient who has given his/her written consent before any specific procedure of the
             protocol.

        Exclusion Criteria:

          1. Severe uncontrolled infection.

          2. Pregnant or breast-feeding females.

          3. Allergy to this medicine.

          4. Diarrhea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei LUO, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei LUO, M.D.</last_name>
    <phone>+862087343483</phone>
    <email>luowei2@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei LUO, M.D.</last_name>
      <phone>+862087343483</phone>
      <email>luowei2@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>March 27, 2013</last_update_submitted>
  <last_update_submitted_qc>March 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Wei LUO</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rhGM-CSF</keyword>
  <keyword>Oral Mucositis</keyword>
  <keyword>Primary Nasopharyngeal Cancers</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

